Crown Healthcare, a Kenyan medical products distributor, has secured a US$10 million investment from Impact Fund Denmark to accelerate construction of a large-scale pharmaceutical manufacturing plant.
- •The new plant is aimed at reducing the country’s dependence on imported medicines. It will be positioned to anchor more of the value chain domestically and strengthen availability of quality medicines across East Africa.
- •The deal marks Impact Fund Denmark’s latest push into African healthcare manufacturing, part of its broader strategy to build resilient local supply chains and reduce systemic import reliance.
- •Noblestride Capital served as the deal's advisor, structuring and executing the transaction on behalf of the parties.
“With this investment, we are helping to improve the availability of essential medicines and make the region more resilient to global crises. At the same time, we are creating 600 local jobs; two things that are essential to achieving our vision of contributing to fair and inclusive societies,” Lisbeth Erlands, Managing Director and Co-Head of Healthcare.
Kenya currently imports about 80% of its pharmaceuticals, leaving the country vulnerable to counterfeits, supply-chain shocks, and spikes in global logistics costs.
Crown Healthcare, founded in 1998, has expanded from medical devices into its own branded generics in recent years. By scaling local production, the company aims to boost supply reliability for hospitals and clinics while reducing exposure to international disruptions that have historically delayed procurement during health emergencies.
Impact Fund Denmark , formerly Investment Fund for Developing Countries/nvesteringsfonden for Udviklingslande (IFU), is the Danish development finance institution.
